Skip to content

Clinical and basic study of ulinastatin affecting pulmoary vascular permeability of ARDS complicating sepsis on clinical curative effect and dose-effect relationship

Clinical and basic study of ulinastatin affecting pulmoary vascular permeability of ARDS complicating sepsis on clinical curative effect and dose-effect relationship

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPD-17011387
Enrollment
Unknown
Registered
2017-05-12
Start date
2017-08-01
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, acute respiratory distress syndrome

Interventions

three doses:ulinastatin

Sponsors

The Third Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) aged 18 to 70 years old, men and women there is no limit; (2) in accordance with the above sepsis ARDS diagnostic criteria; (3) sepsis diagnosed ARDS to include test time 12 hours or less; (4) all needs to accept patients with endotracheal intubation and ventilator help to breathe.

Exclusion criteria

Exclusion criteria: (1) pregnant women, lactation and possible pregnancy women; (2) influence the survival of the patients with severe illness (for example, unresectable tumors, blood disease, cerebrovascular disease, leading to long-term lie in bed, dementia, etc.); (3) of acute myocardial infarction (< 1 week); (4) with acute renal failure; (5) AECOPD; (6) from pulmonary fibrosis; (7) clear of valvular heart disease and heart failure; (8)This medicine allergy; (9) in patients with mental illness; (10) doctors think not suitable for patients as the research object.

Design outcomes

Primary

MeasureTime frame
Observe clinical and prognostic indicators;

Secondary

MeasureTime frame
pulmonary vascular permeability evaluation;inflammation index;blood gas analysis;picco;

Countries

China

Contacts

Public ContactWang Zhiyong

The Third Hospital of Hebei Medical University

wzyphd@126.com+86 18533112993

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026